AZN.L - AstraZeneca PLC

LSE - LSE Delayed Price. Currency in GBp
5,159.00
-7.00 (-0.14%)
As of 9:21AM BST. Market open.
Stock chart is not supported by your current browser
Previous Close5,166.00
Open5,200.00
Bid5,158.00 x 6100
Ask5,160.00 x 13000
Day's Range5,155.00 - 5,248.04
52 Week Range3,996.00 - 5,520.00
Volume179,960
Avg. Volume2,531,799
Market Cap65.31B
Beta0.63
PE Ratio (TTM)16.92
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.79 (4.51%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • Reuters2 hours ago

    Astra and Merck win speedy review for Lynparza in breast cancer

    U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018. The medicine, which is being jointly developed and marketed with Merck under a deal struck in July, is the first poly ADP-ribose polymerase (PARP) drug to be considered for use outside ovarian cancer. Lynparza is also being tested in prostate and pancreatic cancers, the two companies said on Wednesday.

  • Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
    Zacks2 days ago

    Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion

    Foreign markets remain undeterred by discouraging events, notching up weekly gains.

  • Pharma and medtech industries prepare for hard Brexit
    Reuters2 days ago

    Pharma and medtech industries prepare for hard Brexit

    Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small service businesses are already relocating to stay inside the bloc. MeddiQuest, an eight-person consultancy specialising in medical technology regulations, is in the process of moving from outside Cambridge to Ireland. "A significant part of our business is being an authorised EU representative," Chief Executive Neil Armstrong told Reuters.

  • Bloomberg2 days ago

    Drug Companies Fear Brexit Will Hit Medicine Trade

    Time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.

  • Cancer Space Update: Lung & Breast Cancer Studies in Focus
    Zacks5 days ago

    Cancer Space Update: Lung & Breast Cancer Studies in Focus

    While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

  • Pfizer weighs $15 bln sale of consumer healthcare business
    Reuters8 days ago

    Pfizer weighs $15 bln sale of consumer healthcare business

    The move comes as Germany's Merck KGaA (MRCG.DE) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years. Pfizer's consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.

  • AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
    Zacks9 days ago

    AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation

    AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.

  • Financial Times9 days ago

    [$$] AstraZeneca chief confident risks will pay off

    Pascal Soriot is the first to recognise that a pharmaceutical company must take risks if it is to find the next transformative medicine. "It would be much simpler to sell toothbrushes and toothpastes ...

  • What's Behind AstraZeneca's September Rebound?
    Motley Fool10 days ago

    What's Behind AstraZeneca's September Rebound?

    AstraZeneca's shares finally broke out of their slump in September.

  • Reuters12 days ago

    FTSE at two-month peak as sterling falters

    British shares edged higher on Friday and held to their highest level in two months as political uncertainties linked to Theresa's May's premiership pushed the pound lower, giving a boost to dollar-earning groups such as pharma stocks. The FTSE 100 index (.FTSE) closed 0.2 percent up at 7,522.87 points, with Britain's pound on track for its worst week in a year as the Prime Minister hit back at a plot to topple her, saying she would provide "calm leadership" to the country. "The talk of a leadership plot against the Prime Minister is eroding the pound's value and propping up the FTSE 100," CMC Markets analyst David Madden wrote in a note to clients.

  • Drug industry gives up legal battle over new UK cost curbs
    Reuters13 days ago

    Drug industry gives up legal battle over new UK cost curbs

    Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.

  • Tell us how Brexit will work, British companies demand
    Reuters16 days ago

    Tell us how Brexit will work, British companies demand

    British companies including pharmaceuticals giant AstraZeneca urged the government on Monday to agree a three-year Brexit transitional deal to ease the uncertainty hampering investment decisions and the economy. Britain's biggest companies have become increasingly alarmed by the slow progress of Brexit negotiations and the prospect the country could crash out of the world's biggest trading bloc without a deal in 2019. Prime Minister Theresa May vowed in a speech last month to seek a two-year transition deal to help reduce the disruption, but her efforts were overshadowed by a challenge from Foreign Secretary Boris Johnson who has set out his own terms for Britain leaving the European Union.

  • Reuters16 days ago

    Drugs firm AstraZeneca wants three-year Brexit transition

    British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.

  • Drugs firm AstraZeneca wants three-year Brexit transition
    Reuters16 days ago

    Drugs firm AstraZeneca wants three-year Brexit transition

    British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.

  • Should You Be Tempted To Buy AstraZeneca PLC (LSE:AZN) At Its Current Price?
    Simply Wall St.19 days ago

    Should You Be Tempted To Buy AstraZeneca PLC (LSE:AZN) At Its Current Price?

    AstraZeneca PLC (LSE:AZN) is trading with a trailing P/E of 21.6x, which is lower than the industry average of 38.5x. While AZN might seem like an attractive stock to buy,Read More...

  • AstraZeneca's Bevespi Improves Lung Function in Phase III Study
    Zacks21 days ago

    AstraZeneca's Bevespi Improves Lung Function in Phase III Study

    AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.

  • 3 High-Yield Stocks for Aggressive Investors
    Motley Fool23 days ago

    3 High-Yield Stocks for Aggressive Investors

    This drugmaker, telecom, and energy company all sport sky-high yields.

  • 12 Flu Season Facts You Need to Know
    Motley Fool24 days ago

    12 Flu Season Facts You Need to Know

    Here's everything you've ever wanted to know about influenza and flu vaccines.

  • AstraZeneca Stock Upgraded: What You Need to Know
    Motley Fool26 days ago

    AstraZeneca Stock Upgraded: What You Need to Know

    Bernstein sees opportunity in a buyout target.

  • Implied Volatility Surging for AstraZeneca (AZN) Stock Options
    Zacks28 days ago

    Implied Volatility Surging for AstraZeneca (AZN) Stock Options

    AstraZeneca (AZN) needs Investors to pay close attention to the stock based on moves in the options market lately.

  • Oncology Space in Focus this Week on ESMO Presentations
    Zackslast month

    Oncology Space in Focus this Week on ESMO Presentations

    There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.

  • Reuterslast month

    France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

    French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said. About 5 million people globally suffer from some form of lupus, the Lupus foundation of America says, affecting multiple organs and leading to a range of symptoms that can include skin rashes, swollen joints and fevers. Until now, treatments from the likes of GlaxoSmithKline (GSK) and AstraZeneca's MedImmune have focused on the use of monoclonal antibodies, but Neovacs is working on therapeutic vaccines covered by five patent families it calls kinoids, with patent protection until 2032.

  • AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs
    Zackslast month

    AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs

    AstraZeneca (AZN) recently sold its remaining rights to its anaesthetics medicines to Aspen Group for an upfront consideration of $555 million.